Anzeige
Meldung des Tages: Der Vorteil des Meeresbodens: Wie Tiefsee-Knollen den landbasierten Bergbau übertreffen könnten

Elanco Animal Health News

Aktie
WKN:  A2N6BH ISIN:  US28414H1032 US-Symbol:  ELAN Branche:  Pharmazeutika Land:  USA
19,51 €
-0,018 €
-0,09%
09:43:25 Uhr
Depot/Watchlist
Marktkapitalisierung *
9,49 Mrd. €
Streubesitz
-
KGV
24,08
Index-Zuordnung
-

Elanco Animal Health News

23.09.25 - PR Newswire
Elanco Announces FDA Approves Improved Zenrelia™ (ilunocitinib tablets) Label, Removing Vaccine-Induced Disease Language
Elanco Announces FDA Approves Improved Zenrelia™ (ilunocitinib tablets) Label, Removing Vaccine-​Induced Disease Language PR Newswire
08.09.25 - PR Newswire
Elanco Innovation Builds Momentum, Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) Reaches Blockbuster Status
Elanco Innovation Builds Momentum, Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) Reaches Blockbuster Status PR Newswire
27.08.25 - PR Newswire
Splenda® Joins Elanco and HATCH to Support 'Nutrition Secure Indianapolis' to Strengthen Family Health Through Nutrition and Education
Splenda® Joins Elanco and HATCH to Support 'Nutrition Secure Indianapolis' to Strengthen Family Health Through Nutrition and Education PR Newswire
26.08.25 - PR Newswire
Elanco Animal Health Set to Join S&P MidCap 400; Sarepta Therapeutics to Join S&P SmallCap 600
Elanco Animal Health Set to Join S&P MidCap 400; Sarepta Therapeutics to Join S&P SmallCap 600 PR Newswire
26.08.25 - PR Newswire
Elanco to Participate in Morgan Stanley 23rd Annual Global Healthcare Conference
Elanco to Participate in Morgan Stanley 23rd Annual Global Healthcare Conference PR Newswire
07.08.25 - PR Newswire
Elanco Animal Health Reports Second Quarter 2025 Results
Elanco Animal Health Reports Second Quarter 2025 Results PR Newswire
24.07.25 - PR Newswire
Elanco Secures Approval of Zenrelia™ (ilunocitinib) in the European Union (EU), Launching Innovative Canine Dermatology Treatment for Itchy Dogs
Elanco Secures Approval of Zenrelia™ (ilunocitinib) in the European Union (EU), Launching Innovative Canine Dermatology Treatment for Itchy Dogs PR Newswire
10.07.25 - PR Newswire
Elanco Confirms Date and Conference Call for Second Quarter 2025 Financial Results Announcement
Elanco Confirms Date and Conference Call for Second Quarter 2025 Financial Results Announcement PR Newswire
09.07.25 - PR Newswire
Elanco Receives USDA Approval for TruCan™ Ultra CIV H3N2/H3N8 (Canine Influenza Vaccine) Bringing to Market a High Standard of Respiratory Protection
Elanco Receives USDA Approval for TruCan™ Ultra CIV H3N2/H3N8 (Canine Influenza Vaccine) Bringing to Market a High Standard of Respiratory Protection PR Newswire
26.06.25 - PR Newswire
Elanco Releases 2024 Impact Report and Introduces New Framework
Elanco Releases 2024 Impact Report and Introduces New Framework PR Newswire
12.06.25 - PR Newswire
Elanco Receives Positive Opinion on Zenrelia (ilunocitinib) from EU's Committee for Veterinary Medicinal Products (CVMP)
Elanco Receives Positive Opinion on Zenrelia (ilunocitinib) from EU's Committee for Veterinary Medicinal Products (CVMP) PR Newswire
05.06.25 - PR Newswire
Elanco Releases New Report Highlighting the Significance of America's Itchy Dogs and the Need for Itch Relief
Elanco Releases New Report Highlighting the Significance of America's Itchy Dogs and the Need for Itch Relief PR Newswire
28.05.25 - PR Newswire
Elanco Appoints Robert (Bob) VanHimbergen as Chief Financial Officer
Elanco Appoints Robert (Bob) VanHimbergen as Chief Financial Officer PR Newswire
16.05.25 - PR Newswire
Elanco to Participate in the Upcoming Investor Conferences
Elanco to Participate in the Upcoming Investor Conferences PR Newswire
07.05.25 - PR Newswire
Elanco Animal Health Reports First Quarter 2025 Results
Elanco Animal Health Reports First Quarter 2025 Results PR Newswire
05.05.25 - PR Newswire
Elanco Sells Royalty and Milestone Rights for Lotilaner in Human Health to Blackstone; Accelerates Debt Paydown
Elanco Sells Royalty and Milestone Rights for Lotilaner in Human Health to Blackstone; Accelerates Debt Paydown PR Newswire
22.04.25 - PR Newswire
Elanco's Breakthrough Treatment for Deadly Canine Parvovirus Has Saved Thousands of Puppies, Reaffirms Commitment to Increasing the Availability of Canine Parvovirus Monoclonal Antibody for Second Annual National Parvo Awareness Day
Elanco's Breakthrough Treatment for Deadly Canine Parvovirus Has Saved Thousands of Puppies, Reaffirms Commitment to Increasing the Availability of Canine Parvovirus ...

Newssuche

Videos

newspaper
16.04.26 +0,05%
Technical Trading: Treffsichere Signale für Gold
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »